Alfredo Cappariello

Dr. Alfredo Cappariello

Research Laboratories, Pediatric Hospital Bambino Gesù, Rome, Italy;
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Bone
Verified
Journal Article
Closed access
ANDREA DEL FATTOREANDREA DEL FATTORE
ANDREA DEL FATTORE
ACAlfredo Cappariello
Alfredo Cappariello
Anna Maria TetiAnna Maria Teti
Anna Maria Teti

1 September 2014 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
ACAlfredo Cappariello
Alfredo Cappariello
AMAntonio Maurizi
Antonio Maurizi
VVVimal Veeriah
Vimal Veeriah
Anna Maria TetiAnna Maria Teti
Anna Maria Teti

23 August 2005 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
ANDREA DEL FATTOREANDREA DEL FATTORE
ANDREA DEL FATTORE
BPBarbara Peruzzi
Barbara Peruzzi
Nadia RucciNadia Rucci
Nadia Rucci
IRI Recchia
I Recchia
ACAlfredo Cappariello
Alfredo Cappariello
Anna Maria TetiAnna Maria Teti
Anna Maria Teti
Background: Osteopetrosis, a genetic disease characterised by osteoclast failure, is classified into three forms: infantile malignant autosomal recessive osteopetrosis (ARO), intermediate autosomal recessive osteopetrosis (IRO), and autosomal dominant osteopetrosis (ADO). Methods: We studied 49 patients, 21 with ARO, one with IRO, and 27 with type II ADO (ADO II). Results: Most ARO patients bore known or novel (one case) ATP6i (TCIRG1) gene mutations. Six ADO II patients had no mutations in ClCN7, the only so far recognised gene implicated, suggesting involvement of yet unknown genes. Identical ClCN7 mutations produced differing phenotypes with variable degrees of severity. In ADO II, serum tartrate resistant acid phosphatase was always elevated. Bone alkaline phosphatase (BALP) was generally low, but osteocalcin was high, suggesting perturbed osteoblast differentiation or function. In contrast, BALP was high in ARO patients. Elevated osteoclast surface/bone surface was noted in biopsies from most ARO patients. Cases with high osteoclasts also showed increased osteoblast surface/bone surface. ARO osteoclasts were morphologically normal, with unaltered formation rates, intracellular pH handling, and response to acidification. Their resorption activity was greatly reduced, but not abolished. In control osteoclasts, all resorption activity was abolished by combined inhibition of proton pumping and sodium/proton antiport. Conclusions: These findings provide a rationale for novel therapies targeting pH handling mechanisms in osteoclasts and their microenvironment.

1 November 2017 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
ACAlfredo Cappariello
Alfredo Cappariello
ALAlexander Loftus
Alexander Loftus
MMMaurizio Muraca
Maurizio Muraca
AMAntonio Maurizi
Antonio Maurizi
NRNadia Rucci
Nadia Rucci
Anna Maria TetiAnna Maria Teti
Anna Maria Teti
Extracellular vesicles (EVs) are newly appreciated regulators of tissue homeostasis and a means of intercellular communication. Reports have investigated the role of EVs and their cargoes in cellular regulation and have tried to fine-tune their biotechnological use, but to date very little is known on their function in bone biology. To investigate the relevance of EV-mediated communication between bone cells, we isolated EVs from primary mouse osteoblasts and assessed membrane integrity, size, and structure by transmission electron microscopy (TEM) and fluorescence-activated cell sorting (FACS). EVs actively shuttled loaded fluorochromes to osteoblasts, monocytes, and endothelial cells. Moreover, osteoblast EVs contained mRNAs shared with donor cells. Osteoblasts are known to regulate osteoclastogenesis, osteoclast survival, and osteoclast function by the pro-osteoclastic cytokine, receptor activator of nuclear factor κ-B ligand (Rankl). Osteoblast EVs were enriched in Rankl, which increased after PTH treatment. These EVs were biologically active, supporting osteoclast survival. EVs isolated from rankl–/– osteoblasts lost this pro-osteoclastic function, indicating its Rankl-dependence. They integrated ex vivo into murine calvariae, and EV-shuttled fluorochromes were quickly taken up by the bone upon in vivo EV systemic administration. Rankl–/– mice lack the osteoclast lineage and are negative for its specific marker tartrate-resistant acid phosphatase (TRAcP). Treatment of rankl–/– mice with wild-type osteoblast EVs induced the appearance of TRAcP-positive cells in an EV density-dependent manner. Finally, osteoblast EVs internalized and shuttled anti-osteoclast drugs (zoledronate and dasatinib), inhibiting osteoclast activity in vitro and in vivo. We conclude that osteoblast EVs are involved in intercellular communication between bone cells, contribute to the Rankl pro-osteoclastic effect, and shuttle anti-osteoclast drugs, representing a potential means of targeted therapeutic delivery. © 2017 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.

17 January 2012 in Nature Communications
Verified
Journal Article
Open access
PDF file
BPBarbara Peruzzi
Barbara Peruzzi
ACAlfredo Cappariello
Alfredo Cappariello
ANDREA DEL FATTOREANDREA DEL FATTORE
ANDREA DEL FATTORE
Nadia RucciNadia Rucci
Nadia Rucci
FBFabrizio De Benedetti
Fabrizio De Benedetti
Anna Maria TetiAnna Maria Teti
Anna Maria Teti
Interleukin-6 (IL-6) and c-Src impair osteoblast maturation in vitro and in vivo. Given the similar effects of these factors, they are likely to establish a functional loop to maintain osteoblasts in a less mature status. Here we describe a pathway whereby c-Src stimulates IL-6 expression through the STAT3 factor, which, in response to IL-6 induces insulin-like growth factor 5 (IGFBP5), a c-Src activating factor that amplifies this loop only in immature osteoblasts. In contrast, in mature osteoblasts, IGFBP5 is enhanced by Runx2, but is no longer able to stimulate c-Src activation, as this tyrosine kinase at this stage is downregulated. We find that the IGFBP5 produced by osteoblasts stimulates osteoclastogenesis and bone resorption, acting as an osteoblast–osteoclast coupling factor. Finally, we demonstrate that the integrated actions of c-Src, IL-6 and IGFBP5 also have a role in vivo. We conclude that this pathway is relevant for bone metabolism, both in physiological and in pathological conditions.

12 August 2014 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
Nadia RucciNadia Rucci
Nadia Rucci
MCMattia Capulli
Mattia Capulli
SGSara Gemini-Piperni
Sara Gemini-Piperni
ACAlfredo Cappariello
Alfredo Cappariello
PLPatrick Lau
Patrick Lau
Anna Maria TetiAnna Maria Teti
Anna Maria Teti
Mechanical loading represents a crucial factor in the regulation of skeletal homeostasis. Its reduction causes loss of bone mass, eventually leading to osteoporosis. In a previous global transcriptome analysis performed in mouse calvarial osteoblasts subjected to simulated microgravity, the most upregulated gene compared to unit gravity condition was Lcn2, encoding the adipokine Lipocalin 2 (LCN2), whose function in bone metabolism is poorly known. To investigate the mechanoresponding properties of LCN2, we evaluated LCN2 levels in sera of healthy volunteers subjected to bed rest, and found a significant time‐dependent increase of this adipokine compared to time 0. We then evaluated the in vivo LCN2 regulation in mice subjected to experimentally‐induced mechanical unloading by (1) tail suspension, (2) muscle paralysis by botulin toxin A (Botox), or (3) genetically‐induced muscular dystrophy (MDX mice), and observed that Lcn2 expression was upregulated in the long bones of all of them, whereas physical exercise counteracted this increase. Mechanistically, in primary osteoblasts transfected with LCN2‐expression‐vector (OBs‐Lcn2) we observed that Runx2 and its downstream genes, Osterix and Alp, were transcriptionally downregulated, and alkaline phosphatase (ALP) activity was less prominent versus empty‐vector transduced osteoblasts (OBs‐empty). OBs‐Lcn2 also exhibited an increase of the Rankl/Opg ratio and IL‐6 mRNA, suggesting that LCN2 could link poor differentiation of osteoblasts to enhanced osteoclast stimulation. In fact, incubation of purified mouse bone marrow mononuclear cells with conditioned media from OBs‐Lcn2 cultures, or their coculture with OBs‐Lcn2, improved osteoclastogenesis compared to OBs‐empty, whereas treatment with recombinant LCN2 had no effect. In conclusion, our data indicate that LCN2 is a novel osteoblast mechanoresponding gene and that its regulation could be central to the pathological response of the bone tissue to low mechanical forces. © 2014 American Society for Bone and Mineral Research